Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Overview of smoking cessation management in adults

INTRODUCTION

Cigarette smoking is the leading preventable cause of mortality. Smokers who stop smoking reduce their risk of developing and dying from tobacco-related diseases [1,2]. Approximately 70 percent of smokers say in surveys that they want to quit, and over 40 percent of smokers report that they tried to quit in the past year and intentionally did not smoke for at least one day [3]. However, the long-term success rate of any one unaided quit attempt is low, with only 3 to 7 percent of smokers who make an attempt still abstinent one year later. With optimal treatment, one-year abstinence rates after a single quit attempt can exceed 30 percent, yet only 25 percent of smokers who try to quit seek help and even fewer use the most effective treatments [3,4].

Meta-analyses of clinical trials have found that behavioral counseling and pharmacotherapy (with nicotine replacement, bupropion, or varenicline) each has strong evidence of efficacy for smoking cessation, and that the combination of the two methods produces the best results [5,6].  

This topic provides an overview of smoking cessation management in adults, including the choice of therapy and how to implement treatment. Management of smoking cessation in adolescents and pregnant women is discussed separately. (See "Management of smoking cessation in adolescents" and "Smoking and pregnancy", section on 'Smoking cessation'.)

The patterns of tobacco use and behavioral and pharmacologic treatments for smoking cessation are presented in detail separately. (See "Patterns of tobacco use" and "Smoking cessation counseling strategies in primary care" and "Pharmacotherapy for smoking cessation in adults".)

ASSESSMENT OF USE AND EXPOSURE

The United States Preventive Health Services guidelines recommend that tobacco use status of every patient treated in a healthcare setting be assessed and documented at every visit [7]. This practice has been shown to increase the likelihood of smoking-related discussions between patients and physicians and to increase smoking cessation rates [8-10].

                         

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Mar 2014. | This topic last updated: Aug 16, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2004; :CD003041.
  2. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142:233.
  3. Rigotti NA. Clinical practice. Treatment of tobacco use and dependence. N Engl J Med 2002; 346:506.
  4. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. US Department of Health and Human Services 2008. Available at: www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf (Accessed on October 17, 2011).
  5. Stead LF, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev 2012; 10:CD008286.
  6. Suls JM, Luger TM, Curry SJ, et al. Efficacy of smoking-cessation interventions for young adults: a meta-analysis. Am J Prev Med 2012; 42:655.
  7. A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA 2000; 283:3244.
  8. Lancaster T, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev 2004; :CD000165.
  9. Robinson MD, Laurent SL, Little JM Jr. Including smoking status as a new vital sign: it works! J Fam Pract 1995; 40:556.
  10. Okuyemi KS, Ahluwalia JS, Wadland WC. The evaluation and treatment of tobacco use disorder. J Fam Pract 2001; 50:981.
  11. West R. Assessment of dependence and motivation to stop smoking. BMJ 2004; 328:338.
  12. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991; 86:1119.
  13. Henningfield JE, Miyasato K, Jasinski DR. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J Pharmacol Exp Ther 1985; 234:1.
  14. Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, Washington, DC 1994.
  15. White AR, Rampes H, Liu JP, et al. Acupuncture and related interventions for smoking cessation. Cochrane Database Syst Rev 2011; :CD000009.
  16. Tahiri M, Mottillo S, Joseph L, et al. Alternative smoking cessation aids: a meta-analysis of randomized controlled trials. Am J Med 2012; 125:576.
  17. Hajek P, Stead LF. Aversive smoking for smoking cessation. Cochrane Database Syst Rev 2004; :CD000546.
  18. Aveyard P, Bauld L. Incentives for promoting smoking cessation: What we still do not know. Cochrane Database Syst Rev 2011; :ED000027.
  19. Volpp KG, Troxel AB, Pauly MV, et al. A randomized, controlled trial of financial incentives for smoking cessation. N Engl J Med 2009; 360:699.
  20. Barnes J, Dong CY, McRobbie H, et al. Hypnotherapy for smoking cessation. Cochrane Database Syst Rev 2010; :CD001008.
  21. Prochaska JJ. Smoking and mental illness--breaking the link. N Engl J Med 2011; 365:196.
  22. Gierisch JM, Bastian LA, Calhoun PS, et al. Smoking cessation interventions for patients with depression: a systematic review and meta-analysis. J Gen Intern Med 2012; 27:351.
  23. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev 2010; :CD007253.
  24. Barth J, Critchley J, Bengel J. Psychosocial interventions for smoking cessation in patients with coronary heart disease. Cochrane Database Syst Rev 2008; :CD006886.
  25. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996; 335:1792.
  26. Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003; 24:946.
  27. Rigotti NA, Munafo MR, Stead LF. Smoking cessation interventions for hospitalized smokers: a systematic review. Arch Intern Med 2008; 168:1950.
  28. Keenan PS. Smoking and weight change after new health diagnoses in older adults. Arch Intern Med 2009; 169:237.
  29. Shi Y, Warner DO. Surgery as a teachable moment for smoking cessation. Anesthesiology 2010; 112:102.
  30. Rigotti NA, Clair C, Munafò MR, Stead LF. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev 2012; 5:CD001837.
  31. Planer D, Lev I, Elitzur Y, et al. Bupropion for smoking cessation in patients with acute coronary syndrome. Arch Intern Med 2011; 171:1055.
  32. Ford CL, Zlabek JA. Nicotine replacement therapy and cardiovascular disease. Mayo Clin Proc 2005; 80:652.
  33. Mohiuddin SM, Mooss AN, Hunter CB, et al. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest 2007; 131:446.
  34. Prescott E, Scharling H, Osler M, Schnohr P. Importance of light smoking and inhalation habits on risk of myocardial infarction and all cause mortality. A 22 year follow up of 12 149 men and women in The Copenhagen City Heart Study. J Epidemiol Community Health 2002; 56:702.
  35. Steinberg MB, Schmelzer AC, Richardson DL, Foulds J. The case for treating tobacco dependence as a chronic disease. Ann Intern Med 2008; 148:554.
  36. Lindson N, Aveyard P, Hughes JR. Reduction versus abrupt cessation in smokers who want to quit. Cochrane Database Syst Rev 2010; :CD008033.
  37. Fu SS, Partin MR, Snyder A, et al. Promoting repeat tobacco dependence treatment: are relapsed smokers interested? Am J Manag Care 2006; 12:235.
  38. Hajek P, Stead LF, West R, et al. Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev 2009; :CD003999.
  39. Stapleton JA, Sutherland G, Russell MA. How much does relapse after one year erode effectiveness of smoking cessation treatments? Long-term follow up of randomised trial of nicotine nasal spray. BMJ 1998; 316:830.
  40. Mikkelsen KL, Tønnesen P, Nørregaard J. Three-year outcome of two- and three-year sustained abstainers from a smoking cessation study with nicotine patches. J Smok Rel Dis 1994; 5:95.
  41. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272:1497.
  42. Agboola S, McNeill A, Coleman T, Leonardi Bee J. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction 2010; 105:1362.
  43. Office of the Surgeon General. Chapter Six: Cardiovascular diseases. In: A Report of the Surgeon General: How Tobacco Smoke Causes Disease. US Department of Health and Human Services 2011. Available at: http://www.surgeongeneral.gov/library/tobaccosmoke/report/chapter6.pdf (Accessed on December 06, 2011).
  44. Tverdal A, Bjartveit K. Health consequences of reduced daily cigarette consumption. Tob Control 2006; 15:472.
  45. Godtfredsen NS, Holst C, Prescott E, et al. Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19,732 men and women from The Copenhagen Centre for Prospective Population Studies. Am J Epidemiol 2002; 156:994.
  46. Gerber Y, Myers V, Goldbourt U. Smoking reduction at midlife and lifetime mortality risk in men: a prospective cohort study. Am J Epidemiol 2012; 175:1006.
  47. Godtfredsen NS, Prescott E, Osler M. Effect of smoking reduction on lung cancer risk. JAMA 2005; 294:1505.